IMA203 TCR-T candidate targeting PRAME (ACTengine)

	Next higher product group	ACTengine® cell therapy product
	Status	2022-03-23 development p1 existent
	Organisation	Immatics N.V. (Nasdaq: IMTX)
	Group	Immatics (Group)
	Source	Immatics N.V.. (3/23/22). "Press Release: Immatics Announces Full Year 2021 Financial Results and Corporate Update". Tübingen & Houston, TX.

Record changed: 2024-06-07

Picture Berlin Partner Top News CareSyntax Raises $61m for Bio Cheese 650x200px

More documents for IMA203 TCR-T candidate targeting PRAME (ACTengine)

[1] Immatics N.V.. (10/24/23). "Press Release: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy". Houston, TX & Tübingen....
[2] Immatics N.V.. (5/2/23). "Press Release: Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine IMA203 TCR-T Targeting PRAME". Houston, TX & Tübingen....
[3] Immatics N.V.. (10/10/22). "Press Release: Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME". Houston, TX & Tübingen....
[4] Immatics N.V.. (8/23/22). "Press Release: Immatics Announces First Cancer Patient Treated with Second-generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME". Houston, TX & Tübingen....
[5] Immatics N.V.. (8/9/22). "Press Release: Immatics Announces Second Quarter 2022 Financial Results and Business Update". Tübingen & Houston, TX....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]